0.00Open0.00Pre Close0 Volume0 Open Interest11.00Strike Price0.00Turnover720.13%IV-64.06%PremiumJul 26, 2024Expiry Date4.30Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8178Delta0.0897Gamma1.47Leverage Ratio-0.2302Theta-0.0003Rho-1.20Eff Leverage0.0011Vega
Altimmune Stock Discussion
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...
Larger Image: tradingview.com...
$Altimmune(ALT.US)$
No comment yet